DigestRedComo funciona
Red
/
Empresas
Ol
No verificado

Ollin Biosciences, Inc.

Sobre qué escribimos

BiotecnologíaEventosIndustriaÓpticaSalud

6 Comunicados de prensa

Ver todos los comunicados de prensa
02/06/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Óptica
Medicina - Varios
Ollin Biosciences Announces Upcoming Presentations of 20-week Data from Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at Clinical Trials at the Summit 2026
Fuente
Ollin Biosciences, Inc.
Editor
Business Wire
1.00
0
27/05/2026
Eventos
Biotecnología
Farmacéutica
Óptica
Salud
Ollin Biosciences to Participate in Upcoming Investor Conferences
Fuente
Ollin Biosciences, Inc.
Editor
Business Wire
1.00
0
08/04/2026
Eventos
Biotecnología
Sanidad
Óptica
Salud
Ollin Biosciences to Participate in Two Upcoming Investor Conferences
Fuente
Ollin Biosciences, Inc.
Editor
Business Wire
1.00
0
30/03/2026
Industria
Salud
Medicina - Varios
Ciencia
Óptica
Biotecnología
Ollin Biosciences Announces Final Data From Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Fuente
Ollin Biosciences, Inc.
Editor
Business Wire
1.00
0
08/01/2026
Ciencia
Biotecnología
Farmacéutica
Óptica
Salud
Medicina - Varios
Eventos
Industria
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
Fuente
Ollin Biosciences, Inc.
Editor
Business Wire
1.00
0
17/09/2025
Ciencia
Sanidad
Farmacéutica
Óptica
Biotecnología
Medicina - Varios
Salud
Industria
Ollin Biosciences Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
Fuente
Ollin Biosciences, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0